ERN1 and systemic lupus erythematosus: Importantly, pharmacological inhibition of IRE1α using KIRA6 reduced mitochondrial ROS formation, NET release (in both human neutrophils and a mouse model of lupus), and autoantibody formation in multiple lupus mouse models.